Moleculin Biotech, Inc. Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31)
Moleculin Biotech, Inc. (MBRX) reported Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) of 80.00% for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-28.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsExpectedVolatilityRate · last filed 2018-03-28
- Moleculin Biotech, Inc. fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2017 was 80.00%.
| Period end | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-31 | 80.00% 10-K · filed 2018-03-28 |
| 2016-12-31 | 0.00% 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |